Insulet (PODD) Tops Q2 EPS by 12c

Insulet (NASDAQ: PODD) reported Q2 EPS of $0.38, $0.12 better than the analyst estimate of $0.26. Revenue for the quarter came in at $396.5 million versus the consensus estimate of $385.26 million.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c